| Jonathan M. N. Rigby |
Mr. Jonathan M. Rigby is a Chairman & Chief Executive Officer at Sernova Biotherapeutics, Inc., a Chairman & Chief Business Officer at BioPlus Acquisition Corp. and a Chairman at Association of Needle-Free Injection Manufacturers. He is on the Board of Directors at Oncolytics Biotech, Inc., ImmunoMolecular Therapeutics, Inc. and Thermalin, Inc. Mr. Rigby was previously employed as a President, Group CEO & Director by Revolo Biotherapeutics Ltd., a Chairman by CollPlant Biotechnologies Ltd., an Independent Non-Executive Director by Xeris Pharmaceuticals, Inc., a President, Chief Executive Officer & Director by SteadyMed Ltd., a President, Chief Executive Officer & Director by SteadyMed Therapeutics, Inc., a Vice President-Business Development by Zogenix, Inc., a Vice President-Business Development by Aradigm Corp., a Head-Business Development & Sales by Profile Therapeutics Plc, and a Principal by Merck & Co., Inc. He received his undergraduate degree from The University of Sheffield and an MBA from the University of Portsmouth. |
| Ross Haghighat |
Ross Haghighat is the founder of CoreTek, Inc. (1994), Aduro BioTech, Inc. (2008), Triton Systems, Inc. (1992), and FRX Polymers, Inc. (2007). Current jobs include Co-Chief Executive Officer & Director at Epiphany Technology Acquisition Corp. (2022), Chairman at FRX Innovations, Inc., Non-Executive Director at Emefcy Ltd. (2015), Director at Avertix Medical Systems, Inc. (2024), Director at SI2 Technologies, Inc. (2009), Director at ACT Ltd., Director at Electriq Global Ltd. (2018), Director, Chief Executive & Financial Officer at Enterprise 4.0 Technology Acquisition Corp. (2023), Managing Partner at Newburyport Partners Pty Ltd., Chief Executive & Financial Officer at BioPlus Acquisition Corp., and Partner at Jasper Capital Partners. Former jobs include Chairman at Sernova Biotherapeutics, Inc. (2025), Chairman at Vitasora Health Ltd. (2010-2014), Director at Sensera, Inc., Director at Mavatar Technologies, Inc., Independent Non-Executive Director at Emefcy Group Ltd., Director at Redrock Biometrics, Inc., Independent Director at CITIC Capital Acquisition Corp., Independent Director at Chinook Therapeutics, Inc. (2009-2023), Non-Executive Director at Fluence Corp. Ltd. (2015-2024), and Senior Engineer at Foster-Miller, Inc. Education includes an MBA from Boston College and undergraduate and graduate degrees from Rutgers State University of New Jersey (1985, 1986). |
| Shawn Mikael Cross |
Mr. Shawn M. Cross is a Chief Financial Officer at Pacira Biosciences, Inc. and an Independent Director at BioPlus Acquisition Corp. He is on the Board of Directors at BioPlus Acquisition Corp. Mr. Cross was previously employed as an Independent Director by Cyclo Therapeutics, Inc., a Chairman & Chief Executive Officer by Applied Molecular Transport, Inc., a Managing Director by JMP Securities LLC, a Chairman & Chief Executive Officer by GT Biopharma, Inc., a Managing Director by Wells Fargo Securities LLC, a Principal by Thomas Weisel Partners LLC, a Principal by Alex. Brown & Sons, Inc., a Principal by Deutsche Bank AG /UK/, a Principal by Deutsche Bank Securities, Inc., and a Principal by University of Washington Medical Center. He received his undergraduate degree from the University of California, Los Angeles and an MBA from Columbia Business School. |
| Louis G. Lange |
Louis G. Lange founded CV Therapeutics, Inc. in 1990, where he worked as Chairman, CEO & Chief Scientific Officer from 1992 to 2009, Cardiogen Sciences, Inc. in 2014, where he worked as Director from 2014 to 2015, Rapidscan Pharma Solutions, Inc. in 2010, where he worked as Chairman, and various other companies. Dr. Lange also currently works at InCarda Therapeutics, Inc., as Director, Maverix Biomics, Inc., as Director from 2014, NewAmsterdam Pharma BV, as Non-Executive Director, and various other companies. Dr. Lange also formerly worked at CymaBay Therapeutics, Inc., as Chairman from 2009 to 2015, CardioDx, Inc., as Chairman, Institute for Systems Biology, as Chairman, and various other companies. Dr. Lange received his undergraduate degree from Rochester Christian University and doctorate degree from Harvard Medical School. |
| Glen Giovannetti |
Glen Giovannetti is currently serving as a Director at XWPharma Ltd., Revolo Biotherapeutics Ltd., Teon Therapeutics, Inc., and Life Science Cares, Inc. He is also an Independent Director at Enterprise 4.0 Technology Acquisition Corp. He previously worked as a Director at Biotechnology Innovation Organization from 2011 to 2014 and as a Partner at Ernst & Young LLP from 1984 to 2020. He completed his undergraduate degree from Linfield College. |
